Authors
Latest:
Radiotherapy Versis Chemotherapy as ConsolidativeTreatment for Stage IIIB-IV Hodgkin’s Disease in First Complete Remission or Good Partial Response: A Study of 559 Patients (H89 Protocol)The role of radiotherapy in combination with chemotherapy in advanced-stage Hodgkin’s disease remains controversial.
Latest:
2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/GermanyBACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than
Latest:
Percutaneous Ablation: Safe, Effective Treatment of Bone TumorsPercutaneous radiofrequency ablation (RFA) of osteoid osteomashas replaced surgical excision as the preferred method for treatment ofthese benign lesions, due to high effectiveness and low morbidity. BothRFA and cryoablation are safe and effective for palliation of pain dueto metastatic disease in patients who have failed conventional therapies.These image-guided treatments can be performed precisely, allowingsafe treatment of complex metastatic tumors. A single ablationtreatment is effective in most patients, is well tolerated, and provides along duration of pain relief.
Latest:
Uveal and Conjunctival Melanoma: Close Together-but Only Distantly RelatedThere has been rapid progress in the treatment of metastasis associated with cutaneous melanoma, including impressive results achieved with targeted molecular therapies and immunotherapies, and it is possible (but still unproven) that patients with metastasis from conjunctival and eyelid melanomas may benefit from these new therapies.
Latest:
2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/GermanyBACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than
Latest:
Update on European Adjuvant Trials With Irinotecan for Colorectal CancerRecent combinations of chemotherapy have significantly improved the response rate and survival time for patients with metastatic colorectal cancer.
Latest:
Counseling Women at High Risk of Ovarian or Endometrial CancerPatient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
Latest:
Advanced Prostate Cancer: New Agents, New QuestionsDrs. Ruch and Hussain provide an excellent overview of the emerging therapeutic agents and targets for advanced prostate cancer.
Latest:
Thoracic Metastases From Sarcoma: a CommentarySurgical resection of isolated pulmonary metastases has been incorporated into the management of cancer for more than 70 years. However, many questions still remain concerning indications, technique, and efficacy for this approach.
Latest:
Commentary (Basil): Management of Early Ovarian CancerDr. Sonoda has provided a thoroughsummary of the managementof early-stage ovariancancer. He highlights the importanceof accurate and completesurgical staging of this disease entity.Laparoscopic staging is discussed asa potential alternative to the classicopen laparotomy staging procedure.In addition, the author includes anextensive review of trials discussingchemotherapy, radiation therapy, andintraperitoneal therapy as adjuvanttreatment for early-stage disease.
Latest:
HPV Vaccines Continue to Improve, But More Uptake RequiredIn this interview we discuss the latest on HPV vaccines for cancer prevention and some of the struggles countries face in achieving widespread adoption.
Latest:
Management of Tumors of the Parapharyngeal SpaceThis paper offers a very good overview of a large topic that encompasses a multitude of tumors, each with its own set of controversial issues in terms of diagnosis and management. The authors discuss the various diagnostic and therapeutic options available for these tumors in a general sense, rather than concentrating on the specifics of each pathology. Although this approach certainly provides a satisfactory overview, it does not delineate the many diagnostic and therapeutic dilemmas that may confront the practicing head and neck surgeon. However, given the space limitations for such a paper, a more detailed discussion probably was infeasible.
Latest:
Management of Locally Advanced Breast CancerMultimodality therapy-ie, surgical excision followed by appropriate systemic therapy and radiotherapy-has an established role in managing patients with locally
Latest:
Minimizing Oral Complications of Cancer TreatmentAggressive cancer therapy places patients at greater risk for oral complications and treatment-related consequences. Unfortunately, prevention and/or treatment of such oral sequelae have become often overlooked priorities of the treatment team.
Latest:
IMRT for Prostate Cancer Possible in Community HospitalsAn estimated 180,400 new prostate cancer cases will be diagnosed in the United States this year, and many of these patients will be diagnosed and treated at community cancer centers.
Latest:
Irinotecan/Cisplatin in Advanced, Treated Gastric or Gastroesophageal Junction CarcinomaWe conducted a phase II study to assess the response rate and toxicity profile of the irinotecan (CPT-11, Camptosar) plus cisplatin combination administered weekly to patients with at least one previous chemotherapy for advanced adenocarcinoma of the stomach or gastroesophageal junction. Patients with histologic proof of adenocarcinoma of the stomach or gastroesophageal junction with adequate liver, kidney, and bone marrow functions were treated with 50 mg/m² of irinotecan plus 30 mg/m² of cisplatin, both administered intravenously 1 day a week for 4 consecutive weeks, followed by a 2-week recovery period.
Latest:
Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI TumorsIrinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly
Latest:
Prostate Cancer and African-American MenThe article by Powell highlights uncertainties about the relative contributions of diagnostic delay and tumor biology to racial disparities in stage at diagnosis among American men with prostate cancer, and explores a variety of factors that may discourage early cancer detection in African-American men. Observations derived from our ongoing prospective studies of prostate cancer diagnosis and treatment outcomes in black and white American veterans and from our experience with prostate cancer screening at the University of Mississippi Hospital and Clinics afford additional insights into these issues and provide a framework for this commentary.
Latest:
Pain Control an Important Aspect of Breast Cancer TreatmentAs part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.
Latest:
The Three Most Common Chemotherapy-Related Skin ReactionsThe increased approval of anticancer agents has led to unprecedented results, with improved quality of life and longer survival times, resulting in millions of individuals living with a diagnosis of cancer. Whereas these novel medical, surgical, and radiation regimens, or combinations thereof, are largely responsible for these remarkable achievements, a new, unexpected constellation of side effects has emerged. Most notably, cutaneous toxicities have gained considerable attention, due to their high frequency and visibility, the relative effectiveness of anti–skin toxicity interventions, and the otherwise decreasing incidence of systemic or hematopoietic adverse events. Optimal care dictates that dermatologic toxicities must be addressed in a timely and effective fashion, in order to minimize associated physical and psychosocial discomfort, and to ensure consistent antineoplastic therapy. Notwithstanding the critical importance of treatment-related toxicities, dermatologic conditions may also precede, coincide, or follow the diagnosis of cancer. This review provides a basis for the understanding of dermatologic events in the oncology setting, in order to promote attentive care to cutaneous health in cancer patients and survivors.
Latest:
Managing AEs Associated With Bispecifics in RRMMClosing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.
Latest:
The Soy, Breast Cancer ConnectionIn this interview we discuss the link between soy consumption and breast cancer, and the impact of soy supplements on gene expression in early-stage disease.
Latest:
Commentary (Kosecoff/Michelson): Current Status of Practice Guidelines in OncologyIt is somewhat bittersweet that an article about the need for cancer guidelines is being written in 1995. On the one hand, it is heartening that Dr. Winn has patiently organized a coherent framework for creating and implementing guidelines. On the other hand, it is quite bitter medicine to realize, as Dr. Winn points out, that even today, "follow-up studies.... have not been able to
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
La fatiga en personas con cáncerLa fatiga relacionada con el cáncer, un problema común y desconcertante que puede presentarse durante y después del tratamiento del cáncer, puede tener aspectos físicos, mentales y emocionales.
Latest:
Developments in the Treatment of Gastric Cancer in EuropeMetastatic gastric cancer is a relatively chemosensitive disease. With current regimens, 25% to 40% of patients can be expected to respond, and median survival of 6 to 8 months is
Latest:
Long-Term Efficacy and Toxicity of the FEC100 RegimenAdjuvant chemotherapy has been shown to be beneficial in patientswith breast cancer, and anthracycline-containing regimens are more effectivethan non–anthracycline-containing ones. The French AdjuvantStudy Group (FASG) compared FEC100 and FEC50 (fluorouracil[5-FU]/epirubicin [Ellence]/cyclophosphamide [Cytoxan, Neosar])in patients with node-positive breast cancer, with an end point of overallsurvival. After a median follow-up of 10 years, the benefit/risk ratio of theFEC100 regimen in patients with positive axillary nodes is strongly positive.Furthermore, a medicoeconomic study showed that the cost per yearof life saved was very low-approximately 1,000 euros.
Latest:
Synergizing Radiation Therapy and Immunotherapy for Curing Incurable CancersRadiation is often considered immunosuppressive, an activity that is most likely a result of the complex interplay of hormesis and the abscopal effect. The abscopal effect, also called the “distant bystander” effect, is a paradoxical effect of radiation on cellular systems whereby local radiation may have an antitumor effect on tumors distant from the site of radiation.
Latest:
Malignant Melanoma: Biology, Diagnosis, and ManagementCutaneous malignant melanoma is a relatively common neoplasm. In the United States in 1995, an estimated 34,000 cases of melanoma will be diagnosed, and 7,200 persons will die of melanoma [1]. Early primary melanoma is highly curable, but once the disease becomes disseminated, it is nearly always fatal. The overall survival rate has more than doubled from 40% in the 1960s to more than 80% today, but this increase is attributable to earlier diagnosis rather than to treatment advances [2].
Latest:
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas CancerThese guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
